blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1005372

EP1005372 - ANTI-CD40L IMMUNOTOXINS FOR THE TREATMENT OF DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.11.2002
Database last updated on 20.09.2024
Most recent event   Tooltip14.03.2008Lapse of the patent in a contracting state
New state(s): IT		published on 16.04.2008  [2008/16]
Applicant(s)For all designated states
Tanox Pharma B.V.
Paasheuvelweg 15
1105 BE Amsterdam / NL
[2000/23]
Inventor(s)01 / DE BOER, Mark
Naarderweg 20
NL-1261 BT Blaricum / NL
02 / DEN HARTOG, Marcel, Theodorus
Jan Persijnlaan 134
NL-1141 WN Monnickendam / NL
[2000/23]
Representative(s)Jorritsma, Ruurd, et al
Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[N/P]
Former [2000/23]Jorritsma, Ruurd, et al
Nederlandsch Octrooibureau Scheveningseweg 82 P.O. Box 29720
2502 LS Den Haag / NL
Application number, filing date98931129.522.06.1998
[2000/23]
WO1998NL00357
Priority number, dateEP1997020189520.06.1997         Original published format: EP 97201895
[2000/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9858678
Date:30.12.1998
Language:EN
[1998/52]
Type: A1 Application with search report 
No.:EP1005372
Date:07.06.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 30.12.1998 takes the place of the publication of the European patent application.
[2000/23]
Type: B1 Patent specification 
No.:EP1005372
Date:02.01.2002
Language:EN
[2002/01]
Search report(s)International search report - published on:EP30.12.1998
ClassificationIPC:A61K47/48, A61P25/02, A61P19/02, A61P35/02
[2001/21]
CPC:
A61K47/6849 (EP,US); A61K47/6825 (EP,US); A61P19/02 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P37/06 (EP) (-)
Former IPC [2000/23]A61K47/48
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/23]
TitleGerman:ANTI-CD40L IMMUNOTOXINE ZUR BEHANDLUNG VON KRANKHEITEN[2000/23]
English:ANTI-CD40L IMMUNOTOXINS FOR THE TREATMENT OF DISEASES[2000/23]
French:IMMUNOTOXINES ANTI-CD40L SERVANT A TRAITER DES MALADIES[2000/23]
Entry into regional phase12.01.2000National basic fee paid 
12.01.2000Designation fee(s) paid 
12.01.2000Examination fee paid 
Examination procedure29.12.1998Request for preliminary examination filed
International Preliminary Examining Authority: EP
12.01.2000Examination requested  [2000/23]
28.09.2000Despatch of a communication from the examining division (Time limit: M04)
26.01.2001Reply to a communication from the examining division
20.04.2001Despatch of communication of intention to grant (Approval: Yes)
02.07.2001Communication of intention to grant the patent
08.10.2001Fee for grant paid
08.10.2001Fee for publishing/printing paid
Opposition(s)03.10.2002No opposition filed within time limit [2003/01]
Fees paidRenewal fee
30.06.2000Renewal fee patent year 03
29.06.2001Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
FR02.01.2002
GR02.01.2002
IT02.01.2002
LI02.01.2002
NL02.01.2002
DK02.04.2002
PT02.04.2002
SE02.04.2002
DE03.04.2002
CY30.06.2002
ES30.07.2002
[2008/16]
Former [2006/32]AT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
FR02.01.2002
GR02.01.2002
LI02.01.2002
NL02.01.2002
DK02.04.2002
PT02.04.2002
SE02.04.2002
DE03.04.2002
CY30.06.2002
ES30.07.2002
Former [2004/10]AT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
GR02.01.2002
LI02.01.2002
NL02.01.2002
DK02.04.2002
PT02.04.2002
SE02.04.2002
DE03.04.2002
CY30.06.2002
ES30.07.2002
Former [2004/04]AT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
GR02.01.2002
LI02.01.2002
NL02.01.2002
DK02.04.2002
PT02.04.2002
SE02.04.2002
DE03.04.2002
ES30.07.2002
Former [2003/46]AT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
GR02.01.2002
LI02.01.2002
NL02.01.2002
DK02.04.2002
PT02.04.2002
SE02.04.2002
DE03.04.2002
Former [2003/30]AT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
GR02.01.2002
LI02.01.2002
NL02.01.2002
PT02.04.2002
SE02.04.2002
DE03.04.2002
Former [2003/19]AT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
GR02.01.2002
LI02.01.2002
NL02.01.2002
PT02.04.2002
SE02.04.2002
Former [2003/09]AT02.01.2002
BE02.01.2002
CH02.01.2002
FI02.01.2002
LI02.01.2002
NL02.01.2002
PT02.04.2002
SE02.04.2002
Former [2003/06]BE02.01.2002
CH02.01.2002
FI02.01.2002
LI02.01.2002
NL02.01.2002
PT02.04.2002
SE02.04.2002
Former [2003/01]CH02.01.2002
FI02.01.2002
LI02.01.2002
NL02.01.2002
SE02.04.2002
Former [2002/49]FI02.01.2002
NL02.01.2002
SE02.04.2002
Former [2002/48]NL02.01.2002
SE02.04.2002
Former [2002/37]SE02.04.2002
Cited inInternational search[XY]EP0555880  (BRISTOL MYERS SQUIBB CO [US], et al) [X] 1-3 * column 2, lines 22-34 * * column 7, lines 40-54 * * column 12, lines 43-47 * [Y] 1-5,7-17;
 [DY]WO9426910  (XOMA CORP [US], et al) [DY] 1-5,7-17 * page 10, line 1 - page 11, line 15; examples 7,14-17 *;
 [XY]US5474771  (LEDERMAN SETH [US], et al) [X] 1-3 * column 2, lines 15-23 * * column 7, lines 54-58 * * column 13, lines 35-57 * [Y] 1-5,7-17;
 [XY]WO9623071  (BRISTOL MYERS SQUIBB CO [US], et al) [X] 1-3 * page 2, line 34 - page 3, line 11 * * page 5, lines 11-30 * * page 10, lines 20-28 * * page 23, lines 10-13; claims 85-87,99,104-106 * [Y] 1-5,7-17;
 [A]WO9717446  (IDEC PHARMA CORP [US]) [A] 1-17 * the whole document *;
 [PY]  - FRANCISCO J.A. ET AL., "Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single Chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (199709), vol. 272, no. 39, pages 24165 - 24169, XP002081655 [PY] 1-5,7-17 * page 24165 * * See discussion, pages 24168-24169 *

DOI:   http://dx.doi.org/10.1074/jbc.272.39.24165
 [A]  - FRANCISCO, J.A ET AL., "In Vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40", BLOOD, (19970615), pages 4493 - 4500, XP002081656 [A] 1-17 * the whole document *
 [A]  - PREIJERS F W, "Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome -inactivating proteins.", LEUKEMIA AND LYMPHOMA, (1993 MAR) 9 (4-5) 293-304. REF: 101 JOURNAL CODE: BNQ. ISSN: 1042-8194., Switzerland, XP002081657 [A] 4-6 * the whole document *
 [DA]  - GERRITSE K ET AL, "CD40 - CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1996 MAR 19) 93 (6) 2499-504. JOURNAL CODE: PV3. ISSN: 0027-8424., United States, XP002081658 [DA] 14-16 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.93.6.2499
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.